Literature DB >> 8730315

Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients.

M Hassan Alin1, M Ashton, C M Kihamia, G J Mtey, A Björkman.   

Abstract

The study compared the clinical efficacy and safety of oral artemisinin and oral artesunate as well as artemisinin pharmacokinetics during and after resolution of falciparum malaria. Forty adults with symptomatic falciparum malaria were allocated at random to treatment with either oral artemisinin (500 mg single dose on day 1 followed by 250 mg twice daily for 4 d and then another 500 mg single dose on day 6) or with oral artesunate (100 mg single dose on day 1 followed by 50 mg twice daily for 5 d). Patients were admitted to hospital at the Kibaha Designated District Hospital, Kibaha, Tanzania for the duration of treatment. The patients were seen once weekly for 3 more weeks. The time to parasite clearance (PCT) after oral artesunate (26.4 +/- 3.6 h) was shorter (P = 0.002) than after artemisinin (31 +/- 3.6 h). The fever subsidence time (FST) after oral artesunate (18.9 +/- 4.0 h) was also shorter (P = 0.04) than after artemisinin (21.8 +/- 4.6 h). Parasites were detected in 4 (20%) and 7 (35%) patients after completing treatment with artesunate and artemisinin respectively. In these patients the parasitaemia reappeared at the 3rd or 4th week of follow-up. Standard haematology, blood biochemistry and urinalysis, performed before drug intake and again on days 6 and 14, were normal. No clinical abnormality was observed during the study period. Artemisinin plasma concentrations, determined by high performance liquid chromatography with post-column derivatization and detection by ultraviolet light, were followed up to 8 h after drug administration on days 1 and 6. Artemisinin absorption was rapid, the maximum plasma concentrations (Cmax) being attained at about 3 h. Artemisinin areas under the plasma concentration-time curve (AUC) and the Cmax values were about 6 times higher after the first dose on day 1 than on day 6. This decrease in artemisinin plasma concentration is suggestive of an increase in metabolic capacity due to pronounced autoinduction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730315     DOI: 10.1016/s0035-9203(96)90480-0

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  44 in total

1.  Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics.

Authors:  P J de Vries; N N Bich; H Van Thien; L N Hung; T K Anh; P A Kager; S H Heisterkamp
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies.

Authors:  A Moreno; E Badell; N Van Rooijen; P Druilhe
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 3.  Clindamycin as an antimalarial drug: review of clinical trials.

Authors:  Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 4.  Pregnane X receptor and natural products: beyond drug-drug interactions.

Authors:  Jeff L Staudinger; Xunshan Ding; Kristin Lichti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

Review 5.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.

Authors:  Toufigh Gordi; Rujia Xie; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

7.  Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects.

Authors:  T K Dien; P J de Vries; N X Khanh; R Koopmans; L N Binh; D D Duc; P A Kager; C J van Boxtel
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Kevin T Batty; Kaye Kose; Susan Griffin; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

9.  A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Authors:  Doaa A Elsherbiny; Sara A Asimus; Mats O Karlsson; Michael Ashton; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-03-19       Impact factor: 2.745

10.  Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.